MiraChlor-W™ Rx is single-species, pharmaceutical-grade hypochlorous acid for professional wound management — debridement irrigation, physical disruption of biofilm, and removal of microorganisms, with a biocompatibility profile that respects healing tissue.
Used during cleansing and irrigation to loosen and carry away slough, necrotic debris, and exudate from the wound bed.
Helps break down and remove the biofilm matrix that shields bacteria and stalls chronic and infected wounds.
Mechanically reduces the bioburden at the surface, supporting a clean bed for granulation and closure.
At a skin-friendly pH, the working solution is non-cytotoxic at use dilution — so debridement doesn't come at the cost of viable tissue.
For use by healthcare professionals in the management — via debridement — of:
MiraChlor-W's HOCl is produced by LETUS's patented electrolytic process to a single dominant species — without the residual hypochlorite, chlorate, or chloramines that ride along in many solutions.
Patented saltwater electrolysis buffered with sodium bicarbonate — the engine behind consistent, single-species purity.
Apply MiraChlor-W to the wound and surrounding area to cover it.
Use gauze soaked in MiraChlor-W to cleanse the wound during debridement and dressing changes.
Follow with a saline rinse so that no residue of MiraChlor-W remains.
Repeat at each dressing change as part of the overall wound-management plan.
Viability above the 70% threshold at working dilutions.
No mortality, clinical signs, or pathology (IV route).
No erythema or oedema on intracutaneous testing.
No Type IV hypersensitivity (GPMT).
Temperature rise below 0.5 °C.
Substantially equivalent for labeled indications.
GLP studies to ISO 10993 / US FDA guidelines, 2024. Full reports available to clinical partners on request.
Cases from hospital wound-care teams using MiraChlor solution as part of debridement and dressing protocols.
Local infection control and moisture balance with ~1,000 ml MiraChlor (100 ppm). Granulation assessed as strong — no skin graft required.
Infected, exuding bed dressed daily; cleared and accepted a skin graft that progressed.
Debridement plus daily MiraChlor irrigation and antibiotics; closed by day 23.
Lip necrosis caused by an abscess. Lesion rinsed with MiraChlor daily alongside antibiotics; inflammation settled with steady progress to healing.
Paraplegic patient with type 2 diabetes. Daily debridement and MiraChlor soak built a granulating bed; flap placed and supported with negative-pressure therapy and MiraChlor irrigation through to discharge.
Photographs are from clinician-documented real-world use in Vietnam, used as part of standard debridement, dressing, and medical therapy — not controlled clinical trials. Individual results vary. MiraChlor-W is a wound cleanser indicated for use within an overall wound-management plan.
Request a sample, clinical references, or a wholesale account for your practice or facility.
Prefer to talk? Call 877·775·3887 or email [email protected].